
    
      Remestemcel-L will be evaluated in pediatric subjects with acute Graft versus Host Disease
      (aGVHD) following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to
      respond to treatment with systemic corticosteroid therapy.
    
  